Blueprint Medicines Corporation (BPMC) stock is soaring 5.06% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results, which exceeded analyst expectations. The biopharmaceutical company, known for its precision therapy AYVAKIT/AYVAKYT, reported strong revenue growth and raised its full-year guidance.
The company reported a surprise profit of $0.01 per share for Q1 2025, beating the FactSet consensus estimate of a $0.49 loss per share. This marks a significant improvement from the $1.32 loss per share reported in the same quarter last year. Blueprint Medicines' total revenue for the quarter reached $149.4 million, primarily driven by AYVAKIT/AYVAKYT net product sales, representing a 61% year-over-year increase.
In light of the strong performance, Blueprint Medicines has raised its full-year 2025 guidance for AYVAKIT/AYVAKYT net product revenues to $700-$720 million, up from its previous forecast. The company attributes this growth to increasing adoption of AYVAKIT/AYVAKYT in systemic mastocytosis and expects to achieve $2 billion in global net product revenues for the drug by 2030. Additionally, Blueprint Medicines reported a one-time net gain of $50 million from the sale of its equity investment in IDRx, Inc., further strengthening its financial position.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.